NCT05358938View on ClinicalTrials.gov

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 21, 2022

Primary Completion Date

October 6, 2024

Study Completion Date

December 31, 2025

Conditions
Cutaneous MelanomaCutaneous Squamous Cell CarcinomaMerkel Cell Carcinoma
Interventions
OTHER

Exercise

30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles

DRUG

Checkpoint Blockade, Immune

Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER